Witzens-Harig, M., Viardot, A., Keller, U., Wosniok, J., Deuster, O., Klemmer, J., . . . Hess, G. (2021). The mTOR inhibitor temsirolimus added to rituximab combined with dexamethasone, cytarabine, and cisplatinum (R-DHAP) for the treatment of patients with relapsed or refractory DLBCL: Results from the Phase-II STORM Trial. HemaSphere, 5(10), . https://doi.org/10.1097/HS9.0000000000000636
Chicago-Zitierstil (17. Ausg.)Witzens-Harig, Mathias, et al. "The MTOR Inhibitor Temsirolimus Added to Rituximab Combined with Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients with Relapsed or Refractory DLBCL: Results from the Phase-II STORM Trial." HemaSphere 5, no. 10 (2021). https://doi.org/10.1097/HS9.0000000000000636.
MLA-Zitierstil (9. Ausg.)Witzens-Harig, Mathias, et al. "The MTOR Inhibitor Temsirolimus Added to Rituximab Combined with Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients with Relapsed or Refractory DLBCL: Results from the Phase-II STORM Trial." HemaSphere, vol. 5, no. 10, 2021, https://doi.org/10.1097/HS9.0000000000000636.